metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
la/mBC - HR positive - (neo)adjuvant (NA) breast cancer - HR positive la/mBC - HR positive la/mBC - HR positive - (neo)adjuvant (NA)
versus letrozole
	alpelisib plus letrozole
	NEO-ORB (mutant cohort), 2019 Clin Cancer Res 2019; 25:2975-2987-. NCT01923168	RCT	la/mBC - HR positive - (neo)adjuvant (NA)	alpelisib plus letrozole	letrozole	Postmenopausal women with locally confirmed, HR , HER2−, T1c-T3 operable breast cancer with known PIK3CA mutation status, who had not previously received treatment with local or systemic therapy and were considered eligible for neoadjuvant endocrine therapy were included in this study.	-/-	NA	inconclusive	inconclusive 6 % decrease in objective responses (ORR) (PE) inconclusive 45 % decrease in pCR (PE)
	NEO-ORB (wild type cohort), 2019 Clin Cancer Res 2019; 25:2975-2987-. NCT01923168	RCT	la/mBC - HR positive - (neo)adjuvant (NA)	alpelisib plus letrozole	letrozole	Postmenopausal women with locally confirmed, HR , HER2−, T1c-T3 operable breast cancer with known PIK3CA mutation status, who had not previously received treatment with local or systemic therapy and were considered eligible for neoadjuvant endocrine therapy were included in this study.	131 / 126	NA	inconclusive	inconclusive 11 % increase in objective responses (ORR) (PE) inconclusive 68 % increase in pCR (PE)